|
Survival prediction in patients treated by FOLFIRI and bevacizumab for metastatic colorectal cancer (PRODIGE 9) using contrast-enhanced CT texture analysis (SPECTRA). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Roche |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Baxalta; Celgene; Lilly; Merck KGaA; Roche; SERVIER |
Speakers' Bureau - Amgen; Baxalta; Lilly; Merck; Roche/Genentech; Sanofi; SERVIER |
|
|
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; Roche |
Speakers' Bureau - Lilly; Novartis; Pierre Fabre |
Research Funding - Boehringer Ingelheim |
Travel, Accommodations, Expenses - Lilly; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Baxalta; Celgene; Hospira; Ipsen; Lilly; Merck; MSD; Novartis; Roche; Sanofi; Theradiag; Vifor Pharma |
Research Funding - Lilly; Merck; Roche; Theradiag |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Merck; Roche |
|
Travel, Accommodations, Expenses - Amgen; Celgene; Merck; Roche |
|
|
Consulting or Advisory Role - Amgen; Celgene; Lilly; Merck; Novartis; Pfizer; Roche; Sanofi |
Research Funding - Bayer; Roche |
Travel, Accommodations, Expenses - Ipsen; Merck |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Advanced Accelerator Applications |
Travel, Accommodations, Expenses - Amgen; Bayer; Ipsen; Novartis |
|
|
Honoraria - Ipsen; Novartis; Roche; Sanofi |
Consulting or Advisory Role - Ipsen; Pierre Fabre |
Travel, Accommodations, Expenses - Ipsen; Novartis; Roche; Sanofi |
|
|
No Relationships to Disclose |